Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings' receipt of cannabis oils from Canopy Growth is imminent

A collaborative distribution agreement would see the two parties selling both their products into the Australian market.
Medicinal cannabis
The company will soon receive finished cannabis oils from its major shareholder, Canopy Growth Corporation

Auscann Group Holdings Limited (ASX:AC8), a leading medical cannabis company, has received an import permit under its existing import licence.

Following this development, the company will soon receive finished cannabis oils from its major shareholder, Canopy Growth Corporation.

AusCann and Canopy Growth are pursuing opportunities in several key areas in Australia including the importation, distribution and local production of medical cannabis products.

AusCann managing director Elaine Darby said: “Our ongoing relationship with Canopy Growth offers major benefits for AusCann and we are very pleased to be working with Canopy Growth as the Australian market expands.

“The combination of this arrangement and our strong partnership with Tasmanian Alkaloids, positions us to be the leading supplier of affordable, effective and clinically-validated cannabinoid medicines to the Australian market and select international markets.”

AusCann's vertically integrated business model

Initial import of pain relief products

AusCann will initially import the Canopy Growth-supplied AusCann branded products for chronic and neuropathic pain control known as AC 5:5, AC 0:9.5 and AC 15:0.

Each name represents the ratio of tetrahydrocannabinol (THC) to cannabidiol (CBD) in each product.

Potential distribution of Spectrum Cannabis

Canopy Growth and AusCann are working together on developing an arrangement whereby the former will also supply AusCann with its Spectrum Cannabis branded products.

This would see AusCann distributing the product into the Australian market alongside existing AusCann products.

Spectrum Cannabis is Canopy Growth’s international medical brand, operating under a simple colour-coded system to classify its medical cannabis products.

Cashing in on distribution network

The intention is for both parties to undertake the distribution of AusCann and Spectrum products through existing and future distribution networks.

This includes AusCann’s extensive distribution network, recently broadened through the establishment of a relationship with Australian Pharmaceutical Industries (ASX:API).

READ: Auscann Group Holdings to access large Australian pharmaceutical network

Australian Pharmaceutical Industries has a network of 466 high profile brand pharmacies with representation in every state and territory in Australia.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

lab
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use